AstraZeneca has agreed to pay $2.7 billion for Californian biotech ZS Pharma, in a deal which will bolster the drug maker’s cardiovascular disease portfolio as it faces the loss of exclusivity in the U.S. for its best-selling cholesterol-lowering drug Crestor.
from WSJ.com: US Business http://ift.tt/1NwmPoX
via IFTTT
No comments:
Post a Comment